~~<i id='F2798C44DF'><strike id='F2798C44DF'><tt id='F2798C44DF'><pre id='F2798C44DF'></pre></tt></strike></i>~~

Home» comprehensive» hotspot

hotspot

author：explore 2025-09-30 11:02:28 Page View：73724

Damian Garde of STAT talks with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho at STAT in NYC. — Damian Garde of STAT, left, talked with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho about the GLP-1 weight loss market. Michelle C. Gevint for STAT

NEW YORK — Will the world actually soon spend $100 billion a year on the new obesity medicines?

Plenty of people in pharma and at the banks that invest in it seem to think so. Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030.

Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Helping hospitals and community health centers plan for resilience
Next article： DIEP, the 'gold standard' of breast reconstruction, is under threat

Wikipedia

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

FILE-Abortion-rightsprotestersfillIndianaStatehousecorridorsandcheeroutsidelegislativechambers,Frida

How corporate America is slashing DEI workers amid backlash to diversity programs

2:36Anemptyconferenceroomisseeninthisundatedstockphoto.Pgiam/STOCKPHOTO/GettyImagesYearsafterthedeat

Affirmative action in medical school literally saved lives

AdobeThepastseveralmonthshavebeengrimforhealthintheU.S.InDecember,theCentersforDiseaseControlandPrev

Second House panel advances two

Rep.CathyMcMorrisRodgers(R-Wash.)chairsaHousepanelthatadvancedtelehealthlegislation.SusanWalsh/APWAS